BIIB34:BVMF
Biogen Inc BDR
R$ २४४.८०
०.००%
(०.००) 1D
नोभेम्बर १८, १६:५६:०० GMT-३ · BRL
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for BIIB34...
Open
R$ २४४.८०
High
R$ २४४.८०
Low
R$ २४४.८०
Mkt. cap
३७.१६ अरब
Avg. vol.
९.००
Volume
१५.००
52-wk high
R$ २४४.८०
52-wk low
R$ १४७.५०
Shares outstanding
१४.७८ करोड
No. of employees
८ हजार
Open
R$ २४४.८०
High
R$ २४४.८०
Low
R$ २४४.८०
Mkt. cap
३७.१६ अरब
Avg. vol.
९.००
Volume
१५.००
52-wk high
R$ २४४.८०
52-wk low
R$ १४७.५०
Shares outstanding
१४.७८ करोड
No. of employees
८ हजार
News stories
From web sources and news partners
Yahoo Finance
·
१८ मिनेट पहिले
Biogen reports two-year Phase II data for diranersen in Alzheimer’s
Trefis
·
१ घण्टा पहिले
Should Biogen Stock Holders Look At Amgen Instead?
Yahoo Finance
·
६ घण्टा पहिले
What Could Biogen (BIIB) Gain From Its New Protein Degrader Research Deal?
Investing.com
·
२० घण्टा पहिले
Needham reiterates Biogen stock rating on Alzheimer’s drug data
Profile
Biogen Inc. is an American multinational biotechnology company based in Cambridge, Massachusetts, United States specializing in the treatment of neurological diseases. The company's primary products are dimethyl fumarate, diroximel fumarate, interferon beta-1a, peginterferon beta-1a, and natalizumab, all for the treatment of multiple sclerosis; nusinersen for the treatment of spinal muscular atrophy; omaveloxolone for the treatment of Friedreich's ataxia; tofersen for the treatment of ALS; and dimethyl fumarate for the treatment of severe plaque psoriasis. The company also produces 5 biosimilars and has collaborations with Genentech for several drugs.
The company is ranked 424th on the Fortune 500 and 845th on the Forbes Global 2000. Wikipedia
About Biogen Inc BDR
CEOChris Viehbacher
Employees७.५ हजार
Founded१९७८
Headquartersक्याम्ब्रिज, म्यासेचुसेट्स, संयुक्त राज्य अमेरिका
SectorHealth Care
Industry-
Websitebiogen.com